Bluebird Bio Inc. (NASDAQ:BLUE) had its price objective increased by Leerink Swann from $67.00 to $80.00 in a report released on Friday morning. They currently have an outperform rating on the stock.

BLUE has been the topic of a number of other research reports. Jefferies Group reaffirmed a buy rating and issued a $80.00 target price on shares of Bluebird Bio in a research note on Friday, September 23rd. Zacks Investment Research lowered Bluebird Bio from a hold rating to a sell rating in a research note on Wednesday, October 5th. SunTrust Banks Inc. reaffirmed a buy rating on shares of Bluebird Bio in a research note on Friday. Maxim Group set a $85.00 target price on Bluebird Bio and gave the company a buy rating in a research note on Thursday, September 22nd. Finally, Cowen and Company reaffirmed an outperform rating on shares of Bluebird Bio in a research note on Friday, September 9th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have given a buy rating to the company. Bluebird Bio has an average rating of Buy and a consensus price target of $91.60.

Shares of Bluebird Bio (NASDAQ:BLUE) traded up 0.58% during midday trading on Friday, hitting $56.90. The stock had a trading volume of 826,483 shares. The stock has a 50-day moving average price of $63.71 and a 200-day moving average price of $50.93. The stock’s market cap is $2.11 billion. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $99.70.

Bluebird Bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. During the same period in the previous year, the company posted ($1.57) EPS. Bluebird Bio’s quarterly revenue was down 68.6% compared to the same quarter last year. Equities analysts forecast that Bluebird Bio will post ($6.19) earnings per share for the current year.

In other Bluebird Bio news, insider Eric Sullivan sold 2,807 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total value of $126,427.28. Following the transaction, the insider now owns 4,656 shares of the company’s stock, valued at $209,706.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of the company. Cupps Capital Management LLC acquired a new position in shares of Bluebird Bio during the third quarter worth about $1,824,000. Gradient Investments LLC acquired a new position in shares of Bluebird Bio during the third quarter worth about $333,000. First Mercantile Trust Co. acquired a new position in shares of Bluebird Bio during the third quarter worth about $129,000. BNP Paribas Arbitrage SA boosted its stake in Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock worth $209,000 after buying an additional 1,619 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in Bluebird Bio by 43.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 145,569 shares of the company’s stock worth $6,302,000 after buying an additional 44,048 shares during the period.

Bluebird Bio Company Profile

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.